Division of Rheumatology, Department of Internal Medicine, University of Michigan.
Center for Clinical Management Research, VA Ann Arbor Healthcare System.
Curr Opin Rheumatol. 2024 May 1;36(3):235-240. doi: 10.1097/BOR.0000000000001000. Epub 2024 Jan 2.
This review will discuss selected emerging molecular targets and associated potential therapeutic agents for rheumatoid arthritis (RA)-directed treatment.
Agents in active development for RA treatment include those targeted to CD40 and CD40 ligand, programmed death protein 1 (PD-1), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Several other molecules with a strong theoretical role in RA pathogenesis and/or demonstrated efficacy in other autoimmune diseases are also being evaluated as potential drug targets in preclinical or translational studies in RA. These targets include interleukin 1 receptor associated kinases 1 and 4 (IRAK1, IRAK4), tyrosine kinase 2 (Tyk2), bradykinin receptor 1 (B1R), OX40 and OX40 ligand.
Identification of molecular targets for RA treatment remains an active area of investigation, with multiple therapeutic agents in clinical and preclinical development.
本文将讨论类风湿关节炎（RA）靶向治疗中选定的新兴分子靶点和相关潜在治疗药物。
目前正在积极开发用于 RA 治疗的药物包括针对 CD40 和 CD40 配体、程序性死亡蛋白 1（PD-1）和粒细胞-巨噬细胞集落刺激因子（GM-CSF）的药物。其他一些在 RA 发病机制中具有很强理论作用或在其他自身免疫性疾病中显示出疗效的分子，也正在作为潜在的药物靶点，在 RA 的临床前或转化研究中进行评估。这些靶点包括白细胞介素 1 受体相关激酶 1 和 4（IRAK1、IRAK4）、酪氨酸激酶 2（Tyk2）、缓激肽受体 1（B1R）、OX40 和 OX40 配体。
RA 治疗的分子靶点的确定仍然是一个活跃的研究领域，有多种治疗药物处于临床和临床前开发阶段。
